Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial
This is an open-label, randomized, controlled, phase 3 trial done at 29 hospitals in China. Patients had pathologically confirmed HER2-positive metastatic breast cancer. They were given pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine. Pyrotininib can be considered an alternative treatment option for patients with HER2-positive metastatic breast cancer.
